肥胖药物治疗五年体重减轻维持情况
本研究在学术体重管理中心对428例超重或肥胖患者使用美国食品药品监督管理局(FDA)批准及超说明书抗肥胖药物(AOMs)治疗,随访平均4.4年,平均体重减轻10.4%,70.8%患者达到≥5%减重目标,48.1%达到≥10%,平均反弹最大减重的51%,40.2%患者维持减重。
要点
- 平均随访4.4年,平均体重减轻10.4%。
- 达到≥5%、≥10%、≥15%、≥20%减重目标的比例分别为70.8%、48.1%、29.9%、17.1%。
- 平均反弹最大减重的51%,40.2%患者维持减重;就诊次数多与更多减重相关。
核心结论
- 在临床实践环境中,使用肥胖药物治疗可在4年以上实现10%或以上的长期临床显著体重减轻。
研究设计与样本
- 队列研究,纳入2014年4月1日至2016年4月1日期间在学术体重管理中心接受FDA批准及超说明书抗肥胖药物治疗的428例超重或肥胖患者。
主要发现
- 平均体重减轻为10.4%,平均随访时长为4.4年。
- 达到≥5%、≥10%、≥15%、≥20%减重目标的比例分别为70.8%、48.1%、29.9%、17.1%。
- 平均反弹最大减重的51%,40.2%的患者维持了体重减轻。
- 多变量回归分析中,就诊次数较多与更多体重减轻相关;二甲双胍、托吡酯和安非他酮与维持≥10%减重的比值增加相关。
关键数值与推荐
- 减重目标≥5%、≥10%、≥15%、≥20%的达标比例分别为70.8%、48.1%、29.9%、17.1%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Long-term treatment of obesity with lifestyle changes alone is unsustainable for most individuals because of several factors including adherence and metabolic adaptation. Medical management of obesity has proven efficacy for up to 3 years in randomized controlled trials. However, there is a dearth of information regarding real-world outcomes beyond 3 years. OBJECTIVE: This work aimed to assess long-term weight loss outcomes over a 2.5- to 5.5-year period with US Food and Drug Administration (FDA)-approved and off-label antiobesity medications (AOMs). METHODS: A cohort of 428 patients with overweight or obesity were treated with AOMs at an academic weight management center with an initial visit between April 1, 2014, and April 1, 2016. Intervention included FDA-approved and off-label AOMs. The primary outcome was percentage weight loss from initial to final visit. Key secondary outcomes included weight reduction targets as well as demographic and clinical predictors of long-term weight loss. RESULTS: The average weight loss was 10.4% at a mean follow-up duration of 4.4 years. The proportions of patients who met the weight reduction targets of 5% or greater, 10% or greater, 15% or greater, and 20% or greater were 70.8%, 48.1%, 29.9%, and 17.1%, respectively. On average, 51% of maximum weight loss was regained, while 40.2% of patients maintained their weight loss. In a multivariable regression analysis, a higher number of clinic visits was associated with more weight loss. Metformin, topiramate, and bupropion were associated with increased odds of maintaining 10% or greater weight loss. CONCLUSION: Clinically significant long-term weight loss of 10% or more beyond 4 years is achievable in clinical practice settings with obesity pharmacotherapy.
引用
- Weintraub MA, D'Angelo D, Tchang BG, et al. Five-year Weight Loss Maintenance With Obesity Pharmacotherapy. J Clin Endocrinol Metab. 2023. PMID: 36810608. doi:10.1210/clinem/dgad100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。